Gilead Sciences (NASDAQ: GILD) of Foster City, CA, has agreed to purchase a clinical biologics manufacturing facility from Genentech in Oceanside, CA, about 36 miles north of San Diego, according to a statement today. The company says it plans to offer jobs to 55 Genentech employees now working at the 70,000 square-foot plant, which Genentech calls its Oceanside Clinical Plant. Terms of the deal, which includes certain plant assets, were not disclosed. Most of the drug candidates Gilead has under development are targeting hepatitis C, HIV, cancer, cardiovascular, and respiratory disorders.
By posting a comment, you agree to our terms and conditions.